 YONKERS, N.Y., March 22, 2021 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq: CFRX, a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the closing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of 5.00 per share, including 1,500,000 shares sold pursuant to the underwriters exercise in full of their option to purchase additional shares. The gross proceeds from the public offering were 57.5 million, before deducting underwriting discounts and commissions and offering expenses payable by ContraFect. All shares in the offering were sold by ContraFect. 